Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.50 |
| ▸ | F10 | P00742 | 4/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.47 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.47 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.47 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.43 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9987587 | 0.99 | F2 (0.49) | F2F10HSD11B1HSD17B1HSD17B2 | |
| SCHEMBL27412237 | 0.81 | MAPT (0.52) | F2F10HSD11B1HSD17B1HSD17B2 | |
| SCHEMBL30932945 | 0.79 | HSD11B1 (0.47) | F2F10HSD11B1HSD17B1HSD17B2 | |
| SCHEMBL1340728 | 0.78 | F2 (0.47) | F2F10HSD11B1HSD17B1HSD17B2 | |
| Hydrochloric Acid SCHEMBL1340940 | 0.77 | F2 (0.47) | F2F10HSD11B1HSD17B1HSD17B2 | |
| SCHEMBL30932939 | 0.75 | HSD11B1 (0.43) | F2F10HSD11B1HSD17B1HSD17B2 | |
| SCHEMBL30932940 | 0.75 | HSD11B1 (0.43) | F2F10HSD11B1HSD17B1HSD17B2 | |
| SCHEMBL27412307 | 0.74 | HSD11B1 (0.44) | F2F10HSD11B1HSD17B1HSD17B2 | |
| SCHEMBL27412265 | 0.74 | F2 (0.46) | F2F10HSD11B1HSD17B1HSD17B2 | |
| SCHEMBL2650342 | 0.74 | PTPN1 (0.44) | ITGB1ITGA4MAPTTP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110301158-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | NOVO NORDISK A/S (DK) | 2011-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301158-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | GCK, GCKR, PDK2 | F2 4792/4885F10 4540/4885HSD11B1 1762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.